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SUMMARY
Comorbidities and their impact on chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a complex disease that is associated with devastating outcomes resulting from lung 
involvement and several comorbidities. Comorbidities could impact on symptomology, quality of life, the complications, the 
management, economic burden and the mortality of the disease. The importance of comorbidities originates from their impact on 
the outcome of COPD. The most frequent comorbidities in COPD are cardiovascular, endocrinological, musculoskeletal, phycological 
disorders and lung cancer. Almost 50% of the COPD patients have 3 or more comorbidities. The recent Global Initiative of 
Obstructive Lung Disease (GOLD) Guideline suggested proactive search and the treatment of the comorbidities. However, there is 
no certain evidence demonstrating that active treatment of comorbidities improve the outcomes of COPD. However, it is well known 
that several comorbidities such as cardiovascular disease and lung cancer have greater impact on mortality caused by COPD. Several 
studies have shown that Charlson Comorbidity index or more 
recenty COPD Specific Comorbidity Index (COTE) has been found 
to be related with mortality of COPD. This concise review intended 
to summarize the most frequent comorbidities in association with 
their impact on COPD.
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INTRODUCTION
COPD is a complex disease that is associated with 
devastating outcomes resulting from lung involvement 
and several comorbidities (1,2). The medical 
dictionaries describe comorbidity as “the coexistence 
of concomitant but pathologically unrelated diseases”. 
In practice the term of comorbidity is used for the 
coexistence of two or more diseases regardless of the 
pathogenic interlink”. COPD has greater number (3.7) 
of comorbidities than non COPD subjects (1.8) (3-5). 
Studies showed that 94% of COPD patients had at 
least one comorbidity and up to 46% had three or 
more (3). The common etiological factors such as 
smoking, aging and reduced physical activities or 
shared inflammatory pathways can be the explanation 
of that relationship (1-3). The importance of 
comorbidities originates from their impact on the 
outcome of COPD. Comorbidities could cause 
additional impairment of patient’s health quality of life, 
morbidity, health economy and mortality (1,3,6).
Gastroesophagial reflux disease (GERD), 
depression, anxiety, cardiovascular disease, and 
pulmonary embolism are associated with increased 
number of COPD exacerbations (6,7). The impact of 
comorbidities in exacerbations whether they mimic 
exacerbations or they precipitate the intensity of 
exacerbation is still a matter of debate (6). 
Comorbidities related with COPD Specific 
Comorbidiy Test (COTE) index revealed an 
increased risk of mortality (2.2 fold) (8). Toward a 
Revolution in COPD Health (TORCH) and 
Understanding Potential Long-term Impacts on 
Function with Tiotropium (UPLIFT) studies showed 
the almost 70% of causes of deaths in COPD were 
non-respiratory and the major non-respiratory 
etiology of mortality was cancer and cardiovascular 
diseases particularly in mild to moderate disease 
(9,10). Recent guidelines recommend actively 
searching and effectively treating common 
comorbidities (1.) However, there is no enough 
evidence to suggest that treatment of COPD would 
reduce comorbidities, the treatment of comorbidities 
improves COPD and, that the presence of COPD 
alters the treatment modalities of comorbidities. 
The best suggested approach in reduction of 
comorbidities in COPD is reduction of common 
risk factors such as smoking, obesity and physical 
inactivity (Table 1).
COPD and RESPIRATORY SYSTEM  
ACOPD can coexist with several respiratory disorders. 
Asthma, bronchiectasis, lung cancer and pulmonary 
fibrosis are among them.  
Asthma
Distinguishing asthma from COPD could be 
problematic in adult patients especially in smokers. 
(11). Physician diagnosed Asthma COPD Overlap 
Syndrome (ACOS) has a prevalence of 20% of 
patients with obstructive lung diseases (asthma or 
COPD). The coexistence of both diseases has worse 
outcome then either disease alone. Those patients 
should not be put on either LABA or LAMA alone and 
inhaled steroids should be placed besides the 
bronchodilator therapy (11).
Lung Cancer
Ageing, smoking, family history and host 
susceptibility have been identified as key risk factors 
for both COPD and lung cancer (12). Several large 
ÖZET
Kronik obstrüktif akciğer hastalığında komorbiditelerin hastalık üzerine etkileri
Kronik obstrüktif akciğer hastalığı (KOAH), akciğer etkilenimi ve çeşitli komorbidetelerden kaynaklanan yıkıcı sonuçları olan kompleks 
bir hastalıktır. Komorbiditeler, semptomları, yaşam kalitesini, komplikasyonları, hastalığın yönetimini, ekonomik yükünü ve mortalitesi-
ni etkilemektedir. Komorbiditelerin önemi, KOAH’ın sonuçları üzerine olan etkilerinden kaynaklanmaktadır. KOAH’ta görülen en sık 
komorbiditeler, kardiyovasküler, endokrinolojik, müsküloskeletal ve psikolojik olanlar ve akciğer kanseridir. KOAH olgularının en az 
%50'sinde üç veya daha fazla komorbidite bulunmaktadır. Yeni GOLD kılavuzu komorbiditelerin proaktif olarak araştırılmasını ve 
tedavisini önermektedir. Ancak bu komorbiditelerin aktif tedavisinin, KOAH’ın sonuçlarını etkilediğine dair kesin bir kanıt yoktur. Öte 
yandan kardiyovasküler hastalıklar ve akciğer kanseri gibi komorbiditeler, KOAH mortalitesi üzerinde önemli etkiye sahiptir. Çeşitli 
çalışmalar, Charlson komorbidite indeksinin veya KAOH spesifik komorbidite indeksinin (COTE) KOAH mortalitesi ile ilişkili olduğunu 
göstermiştir. Bu kısa derleme, KOAH üzerindeki etkileri ile beraber en sık görülen komorbiditeleri özetlemeyi amaçlamıştır.
Anahtar kelimeler: KOAH, komorbidite
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scale studies showed that emphysema and airflow 
obstruction increased the risk of lung cancer (Hazard 
Ratio: 2.8) (12-14). COPD has been found to 
coexistin 9% to 50% of lung cancer population 
(8,15). Lung cancer can be found incidentally in 
COPD patients while dealing with obstructive 
pneumonia or untractable COPD exacerbation. 
Lung cancer is a major comorbidity that can cause 
mortality in COPD patients (16). COPD may limit 
the chance of surgery in patients with lung cancer 
while increasing postoperative complications and 
finally increasing the likelihood of mortality due to 
COPD complications (3,6,17).
Lung Cancer Screening has been reccommended in 
several guidelines. According to the National Lung 
Screening Trial, (NLST) current or former cigarette 
smokers within the past 15 years, 55 to 74 years of 
age, with at least 30 pack-years of smoking patients 
are the high risk criteria for the lung cancer. However, 
those criteria are still not sensitive enough and still 
can miss up to 39% of cancer patients. Therefore, 
several authors suggest adding emphysema to NLST is 
beneficial for improving detection rate (18).
Pulmonary Fibrosis
The combined apprearance of pulmonary fibrosis and 
empysema (CPFE) was first described in 2005 (19). 
This phenomenon would be a different entity than 
simple gathering two smoking associated diseases 
(20). There is upper lobes emphysema and lower lobe 
fibrosis with low carbon monoxide diffusion capacity 
(DLCO) and high risk of pulmonary hypertension and 
lung carcinoma (19). The symptoms of CPFE are more 
likely to resemble IPF showing progressive dyspnea 
and dry cough (21). Paraseptal emphysema is typical 
for CPFE (19,21). It is currently unknown whether 
pirfenidone or nintedanib are efficacious in CPFE 
(21). Lung transplantation is the only therapeutic 
option (6).
COPD and ENDOCRINOLOGY and METABOLISM
Weight loss and muscle wasting are present in 20%-
70% of COPD patients (22). Aging, malnutrition, 
inactivity, smoking, hypoxemia, hypercapnia, 
administration of glucocorticoids and chronic 
comorbidities are associated with downregulation of 
anabolic states (22). This results in decreased testesteron 
levels, diminished bone density and muscle mass. 
COPD can cause late onset hypogonadism. However, 
replacing testesteron is no clear indication in COPD 
(22). Studies showed that adrenal axis was also 
affected by COPD. The cortisol/DHEAS ratio was 
greater among patient with low muscle mass. However, 
there is no evidence that DHEA administration has a 
significant benefit in COPD (23-25).
Body Mass and COPD
Metabolic Syndrome and abdominal obesity is more 
prevalent in mild to moderate COPD (16-24%) than 
severe disease (6%) (26). In early COPD, obesity can 
induce cardiovascular mortality but in the late stages 
of disease, the cachexia takes place and associated 
with increased mortality (27). 
Diabetes Mellitus
The prevalence of diabetes in patients with COPD is 
10-18.7% (28). Glucose metabolism is more dis-
turbed in COPD patients than non-COPD patients. 
Shared risk factors and common inflammatory patho-
physiology could be reason behind that relation. 
TNF-alpha, IL-6, IL-1B, CRP and fibrinogen are most 
studied. Advanced age, hereditary factors, smoking, 
low birth weight are the shared risk factors of both 
diabetes and COPD (29). DM can cause pulmonary 
microangiopathy that results in reduced diffusion 
capacity of carbon monoxide (30). Hence, DM can 
cause phrenic neuropathy that results in diaphragm 
dysfunction (29). DM is also associated with increased 
risk of infectious exacerbations relating increased 
morbidity and mortality (31). Hyperglicemia can 
induced by chronic systemic CS usage. DM can 
develop in 11% of those patients (32,33). There is 
evidence that particularly high dose inhaled steroids 
can increase the risk of type 2 diabetes and can 
worsen the glycemic control (33,34). 
COPD and Vitamin D
Vitamin D hypovitaminosis is a common problem all 
over the world. There has been interest in a possible 
link between vitamin D hypovitaminosis and COPD 
pathogenesis, progression, exacerbations and 
associated comorbidities. The desired vitamin D level 
is above 30 ng/mL. Vitamin D deficiency is described 
as if the 25(OH) vitamin D level under 20 ng/mL. 
Insufficiency is between 20-29 ng/mL (35). COPD 
patients had significantly lower vitamin D levels 
when compared to controls (36). Low food intake, 
aging, staying indoors, increased vitamin D catabolism 
due to glucocorticosteroids, impaired activation by 
renal dysfunction, lower storage capacity in muscles 
or fat tissues due to wasting could be the etiology for 
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vitamin D hypovitaminosis in COPD (36,37). Vitamin 
D deficiency is related with osteoporosis, muscle 
weakness, infection and cardiovascular events in 
COPD. Several studies showed that Vitamin D 
deficiency is related with COPD onset, COPD 
progression and exacerbation. 
Direct sun exposure without sunscreen is needed for 
skin to produce Vitamin D3. The recent Endocrinology 
Guideline in vitamin D deficiency recommends that 
adults above age 50 require daily 600-800 IU 
vitamin D for bone and muscle health. However, in 
order to raise blood vitamin D level over 30 mg/dL 
1500-2000 IU/d vitamin D will be needed (35).
COPD and MUSCULOSKELETAL DYSFUNCTIONS
Common musculoskeletal problems seen in patients 
with chronic obstructive pulmonary disease (COPD) 
are skeletal and respiratory muscle dysfunction, 
postural impairments, decreased flexibility and range 
of motion (38). Skeletal muscle dysfunction directly 
affects exercise performance, is associated with poor 
health status, and is an independent predictor of 
healthcare utilization and mortality (39,40).  Skeletal 
muscle weakness is characterized by reduced muscle 
strength, reduced muscle endurance and the presence 
of muscle fatigue (41). The quadriceps muscle 
weakness is a common feature in patients within all 
stages of COPD and reduced quadriceps strength is 
found to be a useful predictor for mortality in patients 
with COPD (42,43). Also, postural abnormalities 
seen in patients with COPD are important due to 
negative impact on respiration and both components 
should be assessed individually. Changes in body 
and respiratory mechanics and acute/chronic 
cervical, thoracic or costal joint pains may occur 
with postural deviations (38,44).
There are several risk factors in COPD that may 
contribute to skeletal muscle weakness. These include 
smoking, corticosteroids, hypoxia, hypercapnia, 
inflammation, oxidative stress, reduced daily physical 
activity, vitamin D deficiency, nutritional deficitis and 
age (45).
The estimated overall prevalence of skeletal muscle 
weakness in patients with COPD was shown to be 
20%-30% (46,47).
Management of musculoskeletal dysfunction in 
COPD patients, pharmacological (testosterone 
replacement therapy and vitamin D and calcium 
supplementation) and non-pharmacological (exercise 
training, prevention of falls and balance training and 
nutritional counseling) treatments are applied. 
(40,45). Their respective effects on limb muscles are 
summarized in Table 2.
COPD and OSTEOPOROSIS
Osteoporosis is defined a systemic disease by World 
Health Organization, characterized by a low bone 
mineral density and/or microarchitectural deterioration 
of bone tissue, leading to increased bone fragility and 
fracture risk (48). Osteoporosis prevalence increases 
with the severity of COPD (49-51).
Osteoporosis is common in both male and female 
patients with COPD (41). The prevalence of 
osteoporosis in COPD varies between 4% and 59%, 
depending on the diagnostic methods used and the 
severity of the COPD population (52). More than half 
of the patients with COPD recruited for the large 
TORCH trial had osteoporosis or osteopenia as 
determined by DEXA scan (53). Potential contributors 
to osteoporosis in COPD are corticosteroid use, 
inflammation, vitamin deficiency, anemia, smoking, 
and hypogonadism (41,43). 
Prevention and treatment of osteoporosis involves 
both pharmacologic and nonpharmacologic 
interventions. Initially smoking cessation should be 
instituted into non-pharmacological interventions. 
Also overuse and overdose of ICS in COPD must be 
avoided (54). Pharmacological interventions consist 
of calcium and vitamin D supplementation and anti-
resorptive therapy Oral or intravenous 
bisphosphanates are considered as the first line 
treatment for osteoporosis together with vitamin D 
and calcium supplementation. Also teriparatide and 
denosumab are the options. 
COPD and GASTROESOPHAGEAL REFLUX DISEASE
The prevalence of gastroesophageal reflux disease 
(GERD) among COPD patients is significantly higher 
than in the normal population and a potential risk 
factor for exacerbation of COPD. The prevalence of 
GERD in COPD patients ranged between 7.7-30%. 
Also 58% of the COPD patients with GERD have 
asymptomatic reflux disease (55). In COPD patients 
with GERD associated risk factors are old age, female 
gender, many COPD medications except inhaled 
muscarinic antagonists (56).
Lifestyle modification and medical and surgical 
management have all been used to treat GERD. 
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Treatment of the GERD in COPD, no alteration to 
standard acid suppression therapy is not required (56).
COPD and MALNUTRITION
In COPD, patients are usually said to be malnourished 
when their BMI is 20 kg/m2. Malnutrition is present 
in 25-40% of severe COPD patients. Aging, tissue 
hypoxia, decreased physical activity, increased 
resting metabolic rate, chronic inflammatory 
processes, impaired anabolic mechanisms, increased 
work of breathing and energy expenditure, decreased 
appetite cause malnutrition in COPD patients (57). 
Decreased weight and muscle mass effect COPD 
patients undesirably and malnutrition is related with 
increased mortality and morbidity. Energy 
consumption for respiration is 36-76 kkal in healthy 
individuals and 430-720 kkal in COPD patients 
respectively. Moreover, low intake and steroid therapy 
increase muscle wasting. Impaired muscle strenght 
worsens respiratoy failure, treatment response during 
exacerbations and prolongs weaning time from 
mechanical ventilation. Therefore, decreased fat free 
mass is more important than weight loss in COPD 
patients. And also electrolyte imbalance contributes 
muscle weakness (57). Undernourished COPD 
patients have longer hospital stays and more 
readmissions than nourished COPD patients.
Table 1. Summary of frequent comorbidities in COPD (6)
Comorbidity Prevalence % Shared risk factors
Respiratory system
Asthma 20 Small airway obstruction, inflammation
Lung cancer 15-20 Systemic inflammation (NF-KB)
Pulmonary fibrosis 6 Systemic inflammation
PHT 10-91 Hypoxia, endothelial dysfunction, pulmonary arterial dysfunction
Endocrine system
DM 10-19 Corticosteroid use, systemic inflammation, insülin resistance
Obesity 16-24 Hormones, systemic inflammation
Metabolic syndrome 25-57 Systemic inflammation, insülin resistance
Vitamin D deficiency 60 Aging, low food intake, corticosteroid use, immobilization
Musculoskelatal System
Muscle dysfunction 36 Low physical activity, corticosteroid use, hypoxia, hypercapnia, inflammation, smoking
Osteoporosis 4-59 Corticosteroid use, systemic inflammation, vitamin D deficiency
Cardiovascular system
IHD 16-53 Systemic inflammation, vascular endothelial dysfunction
HF 20-32 Systemic inflammation, dynamic hyperinflation
Systemic hypertension 40-60 Loss connective tissue, high arterial stiffness, aging
VTE 3-29 Endothelial dysfunction, immobilization, coagulopathy
Gastrointestinal system
GERD 7.7-30 Decrease low esophageal sphincter relaxations
Malnutrition 10-15 Nutritional imbalance, systemic inflammation
Sleep disorders
Overlap syndrome 0.5-3 Obesity, systemic inflammation
Hematologic system
Anemia 7.5-33 Renal impairment, malnutrition, low testosterone levels, growth hormone level 
abnormalities
Urinary system
CKD 16-39
Anxiety-depression 8-80 Immobilization, hypoxia, increased number of comorbidities, poor quality of life, 
living alone
NK-KB: Nuclear factor KB, PHT: Pulmonary hypertension, DM: Diabetes mellitus, IHD: Ischemic heart disease, HF: Heart failure, 
VTE: Venous thromboembolism, CKD: Chronic kidney disease.
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Oral nutritional supplements (as powders, puddings 
or liquids) can be used to supplement the diet when 
nutrient requirements cannot be satisfied through 
normal food and drink. Enteral (nasogastric, naso-
jejunal, gastrostomy) or parenteral nutrition can be 
used for COPD patients without oral intake (58).
COPD and CARDIOVASCULAR DISEASE
Cardiovascular disease is the most significant 
nonrespiratory contributor to both morbidity and 
mortality in COPD. Ischemic heart disease, heart 
failure, systemic hypertension and atrial fibrillation 
are the most common cardiovascular comorbidities 
in COPD.
COPD and ischemic heart disease (IHD) are both 
highly prevalent and share common risk factors, such 
as exposure to cigarette smoke, older age and 
sedentarism (59). The prevalence of IHD in COPD 
patients ranges between 16%-53%.
Chronic obstructive pulmonary disease (COPD) and 
heart failure (HF) frequently coexist in clinical 
practice (60). COPD and heart failure share some risk 
factors including cigarette smoking, advanced age, 
and systemic inflammation. The prevalence of COPD 
among individuals with HF ranges from 20% to 32% 
of cases, and 10% of hospitalized HF patients also 
suffer COPD (61). Heart failure has been demonstrated 
to worsen the prognosis of COPD (62).
Hypertension is very common in COPD patients, but 
is not associated with increased mortality (63). 
Although the pathophysiological relationship 
between of COPD and hypertension are not yet clear 
described. It seems feasible that accelerated aging, 
loss of connective tissue and increased arterial 
stiffness may predispose patients to systemic 
hypertension and an increased risk of cardiovascular 
disease in COPD patients (63).
Atrial fibrillation and COPD are often coexisted (64). 
The pathogenesis of atrial fibrillation in COPD is 
multifactorial and includes risk factors such as 
hypoxemia, acidosis and reduced FEV1 (64). The 
prevalence of atrial fibrillation in COPD patients has 
been reported to 23.3% (65).
Although having similar disease mechanisms, there 
are differences between IHD and COPD in their 
current treatment strategies, and the most significant 
difference is use of beta-agonists in COPD and beta 
blockers in heart disease (66). The researchs have 
shown that cardioselective beta blockers may be 
beneficial in COPD patients with IHD (67). 
Angiotensin-converting enzyme (ACE) inhibitors 
have been associated with reduced exacerbations 
and mortality in COPD (68).
COPD and SLEEP DISORDERS
Patients with COPD have higher prevalences of sleep 
problems such as insomnia, significant disturbance 
in sleep quality, nightmares and daytime sleepiness 
than the general population (69). Moreover, 
co-existence of obstructive sleep apnea (OSA) and 
COPD is also common and all negative effects of 
sleep do not have an adverse effect in healthy 
individuals but may cause problems in patients with 
COPD (70). Sleep is typically fragmented with 
diminished slow wave and rapid-eye-movement 
(REM) sleep, which likely represents an important 
contributing factor to daytime symptoms such as 
fatigue and lethargy. Furthermore, normal 
physiological adaptations during sleep, which result 
in mild hypoventilation in normal subjects, are more 
pronounced in COPD, which can result in clinically 
important nocturnal oxygen desaturation (NOD). The 
co-existence of OSA and COPD is also common, 
principally because of the high prevalence of each 
disorder, and there is little convincing evidence that 
one disorder predisposes to the other (70).
Proposed mechanisms for NOD are ventilation/
perfusion mismatch, hypoventilation, increased upper 
airway resistance, reduced chemoresponsiveness, 
REM related muscle atonia and greater reduction in 
functional residual capacity during sleep. Hypoxic 
pulmonary vasoconstriction is considered a major 
driver of the development of pulmonary hypertension 
and cor pulmonale in COPD, and NOD also could 
cause nocturnal cardiac arrhythmias, nocturnal 
sudden cardiac death (71).  
General consensus statements suggest screening for 
sleep disordered breathing in COPD patients who 
complain of symptoms typically associated with 
sleep-disordered breathing such as excessive daytime 
somnolence and frequent nocturnal arousals from 
sleep (1).
The first management principle of sleep-related 
breathing disturbances in COPD should be to 
optimise oxygenation. But the concentration of 
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added oxygen should be carefully titrated to bring the 
arterial oxygen tension (PaO2) up into the mildly 
hypoxaemic range in order to minimise the tendency 
towards carbon dioxide retention, particularly during 
sleep (72). In addition to correction of hypoxaemia is 
particularly important and in recent years, 
considerable interest has focussed on the potential 
benefits of noninvasive ventilation (NIV). Nocturnal 
positive pressure ventilation (NPPV) is the delivery of 
mechanically assisted breaths without placement of 
an artificial airway, usually with the use of a fitted 
nasal mask. According to consensus report, 
indications for usage of NPPV include: (a) symptoms 
(e.g. fatigue, dyspnea, or morning headache); (b) 
physiologic criteria (PaCO2 > 55 mmHg or 50-54 
mmHg with NOD), or (c) PaCO2= 50-54 mmHg with 
recurrent hospitalization related to episodes of 
hypercapnic respiratory failure. Sleep quality and 
diurnal PaO2 and PaCO2 levels are better with NIV 
plus supplemental oxygen than with oxygen alone 
(73).
ANXIETY and DEPRESSION IN COPD
Depression and axiety are more prevalent in COPD 
than other diseases and than general population, while 
anxiety and depression increase the worse prognosis 
in COPD, COPD increases the risk of depression (RR= 
1.69). There is a bidirectional relation between anxiety 
(RR= 1,83) depression (RR= 1.27) and COPD (74). It is 
not easy to diagnose depression in COPD patients 
because of the overlapping symptoms between COPD 
and depression. However, the six-item Hamilton 
Depression Subscale (HAM-D-6) appears to be a 
useful screening tool (75). Pulmonary rehabilitation 
programs have also been described for COPD 
patients for co-morbid anxiety and depression. By 
means of progressive exercise, training of respiratory 
function, and psycho-education, patients obtained 
better exercise tolerance, less dyspnea, and better 
quality of life (76).
COPD and ANEMIA
Fatigue and dyspnea are the major symptoms of 
anemia, and these can be related to reduced oxygen 
carrying capacity of blood. Furthermore, this 
symptom complex in patients with COPD will 
inevitably contribute the morbidity and mortality 
associated with impaired quality of life and reduced 
exercise capacity. The prevalence of anemia in 
patients with COPD varies from 7.5% to 33%. 
Anemia of chronic disease (ACD) is probably the 
most common type of anemia associated with COPD. 
ACD is driven by COPD-mediated systemic 
inflammation anemia in COPD is associated with 
greater healthcare resource utilization, impaired 
quality of life, decreased survival, and a greater 
likelihood of hospitalization (77).
CONCLUSION
Nighty three % of the COPD patients have at least 
one comorbidity. It is well known that the number of 
the comorbidities has an inverse relation with the 
outcome of COPD. Some of the comorbidities are 
related with mortality in COPD. Lung Cancer and 
Table 2. Effects of treatments for limb muscle dysfunction in chronic obstructive pulmonary disease (40)
Traetment Mass Strength Excercise tolerance Survival
Exercise + + + ?
Oxygen ? ? + +
Nutrition alone - - - ?
Nutrition + exercise + + + ?
Nutrition + exercise + anabolic hormones + + + ?
Testosterone + + - ?
Growth hormones + - - ?
Ghrelin ? ? ? ?
Megestrol - ? - ?
Creatin ? ? - ?
Antioxidants ? ? ? ?
Vitamin D alone ? ? ? ?
Vitamin D + exercise ? ? ? ?
(+): Studies support that the treatment has a favorable effect on the outcome, (-): Studies support that the treatment has no 
favorable effect on the outcome, (?): There are no supporting data for a treatment effect on the outcome.
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cardiovascular diseases are the best known prognostic 
ones.  Some of the comorbidities are known as an 
impactor of disease management and exacerbations. 
Diabetes mellitus is a best example of it. Osteoporosis 
and the imbalance of body composition have great 
impact on quality of life. Depression and anxiety are 
often overlooked and are well related with the rate of 
exacerbation and symptom management. Therefore, 
eventhough the evidence is not well established, the 
current guidelines recommend the active search of 
the common comorbidities in COPD.
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